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Abstract
Background: Syndromic obesity is an umbrella term used to describe cases where obesity occurs with additional
phenotypes. It often arises as part of a distinct genetic syndrome with Prader-Willi syndrome being a classical example.
These rare forms of obesity provide a unique source for identifying obesity-related genetic changes. Chromosomal
microarray analysis (CMA) has allowed the characterization of new genetic forms of syndromic obesity, which are due
to copy number variants (CNVs); however, CMA in large cohorts requires more study. The aim of this study was to
characterize the CNVs detected by CMA in 279 patients with a syndromic obesity phenotype.
Results: Pathogenic CNVs were detected in 61 patients (22%) and, among them, 35 had overlapping/recurrent CNVs.
Genomic imbalance disorders known to cause syndromic obesity were found in 8.2% of cases, most commonly deletions
of 1p36, 2q37 and 17p11.2 (5.4%), and we also detected deletions at 1p21.3, 2p25.3, 6q16, 9q34, 16p11.2 distal
and proximal, as well as an unbalanced translocation resulting in duplication of the GNB3 gene responsible for a
syndromic for of childhood obesity. Deletions of 9p terminal and 22q11.2 proximal/distal were found in 1% and
3% of cases, respectively. They thus emerge as being new putative obesity-susceptibility loci. We found additional
CNVs in our study that overlapped with CNVs previously reported in cases of syndromic obesity, including a new
case of 13q34 deletion (CHAMP1), bringing to 7 the number of patients in whom such defects have been
described in association with obesity. Our findings implicate many genes previously associated with obesity (e.g. PTBP2,
TMEM18, MYT1L, POU3F2, SIM1, SH2B1), and also identified other potentially relevant candidates including TAS1R3, ALOX5AP,
and GAS6.
Conclusion: Understanding the genetics of obesity has proven difficult, and considerable insight has been obtained from
the study of genomic disorders with obesity associated as part of the phenotype. In our study, CNVs known to be causal
for syndromic obesity were detected in 8.2% of patients, but we provide evidence for a genetic basis of obesity in as many
as 14% of cases. Overall, our results underscore the genetic heterogeneity in syndromic forms of obesity, which imposes a
substantial challenge for diagnosis.
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Background
Obesity is a highly heritable multifactorial disorder defined
by a body mass index (BMI) of ≥30 kg/m2, which predis-
poses to many diseases. Rare and common genetic vari-
ants associated with obesity identified to date have
increased our understanding of the mechanisms by which
obesity develops. Copy number variants (CNVs) in a num-
ber of chromosomal regions are known to be involved in
highly penetrant and individually rare, both isolated and
syndromic forms of obesity [1–3]. The latter describes
cases where obesity co-occurs with additional phenotypes
(e.g., intellectual and developmental disabilities (IDDs),
dysmorphism, congenital anomalies) often arising as part
of a distinct syndrome, from which Prader-Willi syndrome
(PWS; OMIM #176270) is a classical example. Until re-
cently, only a few genomic disorders other than PWS were
known to contribute to increased risk of obesity, including
the known microdeletion syndromes 1p36 (OMIM
#607872), 2q37 (OMIM #600430), 6q16 (SIM1 gene),
9q34 (OMIM #610253; EHMT1 gene), 11p14.1 (OMIM
#612469), and 17p11.2 (OMIM #182290; RAI1 gene).
In recent years, however, numerous unique and rare
recurring/overlapping CNVs have been associated with a
syndromic obesity phenotype in patients through the
widespread use of chromosomal microarray analysis
(CMA) [4–16]. Examples include deletions of chromo-
some band 2p25.3 that include the MYT1L gene (OMIM
#616521), the recurrent 220-kb deletion of distal
16p11.2 including the SH2B1 gene (OMIM #613444),
and the recurrent 600-kb 16p11.2 proximal deletion
(OMIM #611913, gene unknown). Also, a novel genomic
disorder that causes obesity, ID and seizures has been de-
scribed in children carrying a recurrent unbalance trans-
location (8;12)(p23.1;p13.31) that duplicates the GNB3
gene [17]. Overlapping 1p21.3 deletions comprising the
DPYD and MIR137 genes have been detected in patients
with a phenotype consisting primarily of obesity, ID, and
autism spectrum disorder (ASD) [18, 19]. Small 6q16.1
deletions encompassing the POU3F2 gene were identified
in 10 individuals presenting with obesity, hyperphagia and
IDDs [20]. Chromosome 13q34 deletions disrupting the
CHAMP1 gene were linked ID, obesity and mild dys-
morphism in five adult individuals [21].
Syndromic obesity is recognized as an etiologically het-
erogeneous group of disorders for which an obesity-related
genetic change can be identified but only a few genetic
causes have been identified to date. Only one study has
examined the etiology of syndromic obesity with CMA in a
cohort of 100 patients specifically selected for obesity [22].
In that study, CNVs were regarded either as pathogenic or
potentially pathogenic in 22% of cases, and several novel
CNVs for which a defined syndrome has not yet been delin-
eated were uncovered. Herein, we report our experience
over the past 5 years using CMA to identify CNVs in 279
patients referred with syndromic obesity. This study adds
to the current knowledge of CNVs linked to obesity and
provides evidence for association with obesity at new and
previously identified candidate loci.
Methods
Cohort enrollment and description
Only patients who tested negative for PWS (methylation
analysis of SNURF-SNRPN exon 1 by our laboratory)
were included in our study whether or not they had a
positive clinical score for PWS. This test population had
a mean age of 9 years (range 8 days to 40 years old),
55% of cases represented by male patients (male/female
ratio = 1.2). The 2000 Centers for Disease Control and
Prevention (CDC) growth charts (available at https://
www.cdc.gov/growthcharts/) were used to plot weight-
for-age, height-for-age, weight-for-height, BMI-for-age,
and occipito-frontal head circumference (OFC) [23]. We
stratified our cohort into 4 age groups: (1) infants (n = 19)
< 2 years old (mean age 13 months; 9 males and 9
females); (2) children (n = 153) aged 2–9 years (mean age
6 years; 80 males and 73 females); (3) adolescents (n = 98)
aged 10–19 years (mean age 9 years; 61 males and 37
females); (4) adults (n = 10) > 20 years old (mean age
27 years; 2 males and 8 females In a majority of patients,
recognition of excessive weight gain was based on the
following: (1) infants, the standard deviation (SD) of
weight-for-height Z-scores > ~ 1 (mean + 3.23 SD); (2)
children and adolescents, BMI-for-age percentiles ≥85th
(mean 97.4th and 97.9th percentiles, respectively); (3)
adults, BMI values ≥30 kg/m2 (mean 46.7 kg/m2); In 37
patients, data on weight and/or height were missing but
they had a documented diagnosis of overweight or obesity
made by attending physicians, and 5 other patients aged <
5 years had hyperphagia with an increase probability of
developing obesity. Among a subset of 208 children and
adolescents (BMI ≥ 95th percentile), we further classified
obesity based on the BMI expressed as a percentage above
the 95th BMI percentile according to age and sex, as pre-
viously described [24, 25]: a BMI 100–119% of the 95th
percentile was used to define moderate obesity and a BMI
≥120% of the 95th BMI percentile used to define severe
obesity. Extreme BMIs were calculated by multiplying the
BMI at the 95th percentile by a factor of 1.1 through 1.9
to derive the 110% to 190%, for both genders.
Chromosomal microarray analysis
Any of the following genome-wide array platforms were
used according to their availability: CytoSure ISCA v2
4x180K (Oxford Gene Technology, Oxford, UK), SurePrint
G3 Human CGH 8x60K (Agilent Technologies, Santa
Clara, CA), Affymetrix Mapping 100 K and 500 K arrays
(Affymetrix, Santa Clara, CA, USA). Most cases (85%) were
investigated using high-density oligonucleotide microarrays
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(4x180K OGT platform). DNA was extracted from periph-
eral blood using Autopure LS® (Gentra Systems, Inc.,
Minneapolis, MN). Genomic DNA concentration was mea-
sured by Nanodrop spectrophotometer (ThermoFisher).
Chromosomal microarray testing was performed according
to the manufacturers’ instructions. In oligonucleotide-based
microarrays, two experiments were performed for each
patient sample with reversal of the dye labels for the control
and test samples, raw data were processed and analyzed
using Agilent Feature Extraction and Genomic Workbench
software with the statistical algorithm ADM-2 and sensitiv-
ity threshold of 6.7. Affymetrix SNP array data was analyzed
with the Genotyping Console (GTC) 4.0 software using
default settings and a similarly processed reference sample
data set. Due to the limited probe coverage, CNVs on
chromosome Y were removed from the analysis. We used
the American College of Medical Genetics and Genomics
(ACMG) 2011 guidelines for variant interpretation to clas-
sify variants in 4 categories: pathogenic CNVs (PCNVs),
likely PCNVs, variants of uncertain significance (VUS), and
likely benign CNVs [26]. Healthy and disease variant data-
bases used included the Database of Genomic Variants
(DGV, http://dgv.tcag.ca), the Online Mendelian Inherit-
ance in Man (OMIM, https://www.omim.org/) and the
DatabasE of genomiC varIation and Phenotype in Humans
using Ensembl Resources (DECIPHER, http://decipher.san-
ger.ac.uk) [27–29]. All genomic breakpoints were based on
the human genome build GRCh37 (hg19) (http://geno-
me.ucsc.edu/) [30].
Gene prioritization
Genes affected by the detected CNVs were compared to a
list of genes related to obesity downloaded from the Text-
mined Hypertension, Obesity and Diabetes candidate
gene database (T-HOD) [31] and the Human Genome
Epidemiology encyclopedia Navigator (HUGE, https://
phgkb.cdc.gov/PHGKB) [32]. We specifically searched the
term “obesity” and retrieved 835 genes annotated in
T-HOD and 1920 genes annotated in the HUGE Pheno-
pedia. We also checked the genes affected by CNVs
against a list of 370 genes with evidence for playing a role
in obesity curated from literature [33] and a list of 940
genes in the CNV morbidity map for IDDs generated
from 29,085 cases and 19,584 controls [34].
Results
Cohort and correlation of PCNVs with specific phenotypes
General clinical findings noted in patients are listed in
Table 1 (individual descriptions are provided in Table S1 in
Additional file 1). Although patients’ records were not
always complete and clinical comorbidities could not be
fully assessed, the most commonly reported features associ-
ated with obesity were IDDs, dysmorphism, behavioral phe-
notypes, hyperphagia, neonatal hypotonia, and language
impairments. Hands and feet abnormalities, abnormalities
of the external genitalia and eye/vision problems were often
reported. Macrocephaly was observed in 92 of 206 (45%)
patients, compared to 11 of 206 (5%) patients with micro-
cephaly, and tall stature in 40 of 238 (17%) patients, com-
pared to 22 of 238 (9%) patients with short stature (Z-
scores > or < ±2 SD). No association was found between
these growth parameters in cases with and without PCNVs
using the Fisher’s Exact test (Fig. 1).
In an attempt to determine whether there were pheno-
typic differences associated with the presence of PCNVs,
we compared the frequencies of phenotype pairs segre-
gating together in patients with syndromic obesity
caused by PCNVs against those without PCNVs. We
constructed a matrix representation (heatmap) of the
Chi-square p-values between any given pair of pheno-
types that co-occurred in patients with and without
PCNVs. Out of 133 phenotype pairs that were evaluated
(listed in Table S2 in Additional file 2), 12 had significant
associations for PCNVs with p-values < 0.05 (Fig. 2a).
Next, we constructed using Cytoscape [35] a graphic
representation of these phenotype-phenotype associa-
tions, where a given pair of phenotype was connected
only if they were significant at p < 0.05, to discover the
core phenotype variables in the network (those that
overlapped most between pairs). The most highly corre-
lated phenotypes are hypotonia, language impairments,
abnormalities of the external genitalia, and eye/vision
problems. They also correlated with many additional
phenotype variables including seizures, sleep problems,
tall stature and hands/feet abnormalities (Fig. 2b).
Table 1 Additional phenotypes of patients with syndromic
obesity
Clinical features Total cohort (n) Patients
with PCNVs (n)
Intellectual/developmental disabilities 219 55
Craniofacial dysmorphism 149 49
Behavioral problems 132 29
Hyperphagia 112 27
Infantile hypotonia 88 32
Language impairments 80 28
Hands/ft abnormalities 65 21
Abnormal external genitalia 56 20
Eye/vision problems 51 16
Seizures 31 13
Poor motor skills 29 9
Skeletal anomalies 23 9
Brain abnormalities 19 7
Hearing loss 13 6
Cardiac abnormalities 10 4
Prevalence could not be assess as complete phenotypic data was not available
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Characterization of CNVs in patients with syndromic
obesity
Overall, CMA identified clinically relevant genomic im-
balances in 22% of patients, potentially clinically relevant
CNVs in 2%, VUS in 5% and likely benign CNVs in 11%
(Table 2). All clinically relevant results per individual are
listed in Table 3. The genomic regions associated with
likely PCNVs, VUS and likely benign CNVs are listed in
Additional file 3: Table S3.
Pathogenic CNVs
A total of 68 pathogenic imbalances were detected in 61
patients, the majority of which pathogenic deletions
(72%) and rearrangements smaller than 5-Mb (70%). 31
of the patients (6–12, 14, 15, 18, 23, 28, 30–33, 35, 40–
43, 46–48, 51, 52, 55, 56, 58–60) had previously been
published as separate studies [36–38]. De novo PCNVs
were found in 30 patients, whereas only 6 patients inher-
ited a pathogenic deletion or duplication from an appar-
ently unaffected parent, all of which occurring at
genomic loci which are known to have reduced pene-
trance (16p13.11, 16p11.2, and 22q11.2). The inheritance
status could not be determined in 25 cases.
In 47 patients (24 novel cases), the PCNVs overlapped
with chromosomal regions associated with known gen-
omic disorders, and, among them, 35 patients were
detected with PCNVs at 10 loci that were recurrent
(same breakpoints) or overlapping in 2 or more unre-
lated samples (Fig. 3). We found 23 cases with deletions
known to cause a syndromic obesity phenotype: 1p36
(n = 5), 1p21.3 (n = 2), 2p25.3 (n = 1), 2q37 (n = 5), 6q16
(n = 1), 9q34.3 (n = 1), 16p11.2 breakpoint (BP) 2–3
(n = 1), 16p11.2 BP 4–5 (n = 1), and 17p11.2 (n = 5). The
recurrent translocation t(8;12)(p23.1;p13.31) found in
patient 18 is also known to be involved in the pathogen-
esis of syndromic obesity. In addition, 2 rare deletions at
chromosomes 13q12.3 (patient 24) and 19p13.12 (patient
37) overlapped with deletions of different sizes in pa-
tients from the literature and the DECIPHER database
who were obese (Fig. 4). Mapping of the shortest region
of overlap (SRO) in these cases exposed a 660-kb inter-
val at 13q12.3 (chr13:30,880,255–31,540,272 bp, hg19;
Fig. 4a) comprising 5 genes (KATNAL1, LINC00426,
HMGB1, USPL1, ALOX5AP, and MEDAG), and a 440-
kb interval at 19p13.12 (chr19:15,052,889–
15,492,848 bp, hg19; Fig. 4b) comprising 9 genes
(SLC1A6, CCDC105, CASP14, SYDE1, ILVBL NOTCH3,
EPHX3, BRD4, and AKAP8).
In other 14 patients, the PCNVs did not overlap with a
known genomic imbalance disorder but were de novo in
10 cases or of unknown origin (the remainder), and
involved large and complex chromosomal imbalances.
Among these, we found 4 PCNVs overlapping with pre-
viously identified obesity candidate loci (Fig. 5): a novel
22.3-Mb duplication of 3q11.2q13.31 (patient 49), a
novel 11.6-Mb duplication of 13q11q12.3 (patient 53), a
novel 8.5-Mb deletion of 13q33.2q34 (patient 57), and a
1-Mb duplication of band 14q11.2 (patient 58). Notably,
the duplication region at 13q11q12.3 also overlaps with a
smaller duplication present in our patient 19, who
possessed a second large CNV at the 8p23.1 locus. The
extent of overlap among our cases with those previously
described CNVs is of about 2-Mb in band 3q13.31
(chr3:113,924,534–115,890,384 bp, hg19; Fig. 5a), 1.2-Mb
in band 13q12.12 (chr13:23,706,634–24,910,765 bp, hg19;
Fig. 5b), 2.4-Mb in band 13q34 (chr13:112,725,394–
115,092,648 bp, hg19; Fig. 5c), and 827-kb in band 14q11.2
(chr14:21,424,185–22,250,879 bp, hg19; Fig. 5d). Candidate
genes at these intervals are proposed in the discussion.
Likely pathogenic CNVs
CNVs detected in 6 additional patients were classified as
potentially clinically significant, including a de novo 340-
kb duplication at 16p13.2 comprising the USP7 gene im-
plicated in a known deletion syndrome (OMIM #616863),
a 482-kb paternally inherited duplication of 17q11.2 par-
tially overlapping the gene for neurofibromatosis type I
(NF1), and an 1.1-Mb paternally inherited 20q11.2 dupli-
cation upstream of the ASXL1 gene with a likely role in
20q11.2 duplication syndrome [39]. The inheritance of 3
other CNVs could not be determined. The 3 CNVs were a
489-kb duplication in 21q22.13 including the ID gene
DYRK1A (OMIM #614104), a 703-kb deletion in 7q31.1
affecting the IMMP2L-DOCK4 gene region implicated in
Fig. 1 Comparison of frequencies of each variable among patients with
and without PCNVs. The fractions in parentheses indicate the number of
cases that manifested the phenotype over the total number of cases with
data. P-values for the Fisher’s exact test are shown. Macro/microcephaly
and tall/short stature were defined by the Z-scores > or < ±2 SD
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IDDs [40], and an intragenic deletion of the ASTN2 gene
at 9q33.1 which has also been implicated in susceptibility
to IDDs [41].
Variants of uncertain significance
In 15 patients, we detected CNVs that were classified as
VUS. Of these, 2 were de novo events: a 222-kb 12q21.32
duplication including the CEP290 gene whose mutations
cause Bardet-Biedl syndrome (BBS14; OMIM #615991),
but which was not associated with previously reported
pathogenicity, and a 385-kb 6q27 duplication affecting only
three non-coding RNAs found in a patient who inherited a
second large CNV. There were 3 VUS inherited from
asymptomatic parents intersecting with genes within CNVs
that have previously been implicated with disorders, such
as CACNA2D1 with epilepsy and ID [42], and MACROD2
and LINGO2 with autism [43, 44]. Furthermore, 6 VUS (3
inherited and 3 unknown) contained morbid OMIM genes,
including NFIA, MPZ, PARK2, DPP6, and KANK1.
Additionally, 3 other cases (2 females and 1 male) inherited
large chromosome X duplications from carrier mothers
spanning several morbid OMIM genes but with no
Fig. 2 The heat map constructed from the P-values for the Chi-square statistic test between pairs of phenotypes observed in patients with PCNVs against
those without PCNVs is shown at the top, where P-values < 0.05 are represented by small darker gray or black squares and larger values by light gray
squares (white squares indicate null values or the absence of association between a given pair of phenotype). Graphical representation of the phenotype
network generated using Cytoscape is shown at the bottom, where phenotypes (nodes) are interconnected (edges) if they had significant associations for
PCNVs at P < 0.05. The resulting network has 10 interconnected phenotypes and 8 not connected phenotype variables. Red nodes and edges highlight
the most highly connected phenotypes and their interactions in the network
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evidence for triplosensitivity phenotypes as determined by
the ClinGen Dosage Sensitive Map (http://www.ncbi.nlm.-
nih.gov/projects/dbvar/clingen/) [45].
Likely benign CNVs
We also observed 30 patients with CNVs that might rep-
resent benign variants. The observed CNVs were most
often duplications and < 300-kb in size. In all cases where
it was possible to ascertain the parental status, variants
were inherited from an asymptomatic parent. We found
relevant genes lying within some of these CNVs. Examples
of such genes include: PTEN in which mutations cause
many different disorders including macrocephaly/autism
syndrome (OMIM #605309); VPS13B whose mutations
cause Cohen syndrome characterized by truncal obesity,
joint hypermobility and a pigmentary retinopathy (COH1;
OMIM #216550); CIDEA (OMIM 604440) with a role in
regulating energy balance and adiposity; ULK4 crucial to
brain development with CNVs being identified as risk fac-
tor in schizophrenia [46]; KATNAL2 implicated as suscep-
tibility gene of autism [47].
Identification of candidate genes involved in obesity
susceptibility
A total of 2684 genes were affected by the detected CNVs.
Among these, 234 genes had some previously reported con-
nection to obesity as determined by the overlap with genes
from the T-HOD and HUGE database, as well as a gene list
curated from literature [33], and 172 overlapped with genes
listed in the CNV morbidity map for IDDs [34] (367 genes
in total). Of particular interest are 87 genes that were inter-
sected by different gene sets (Fig. 6). Notably, several
known and candidate genes that have previously been im-
plicated in syndromic obesity were retrieved by this candi-
date gene approach, including SIM1 [48], SH2B1 [49],
PTBP2 [38], PRLH and CAPN10 [50], ACP1 and TMEM18
[12], EHMT1 [51], and GNB3 [17]. Thus, these genes were
considered as more likely to have a role in obesity suscepti-
bility. Pathways analysis in Cytoscape using the plugin
Reactome FI showed that the majority of these genes were
related to metabolic pathways and small molecule meta-
bolic process.
PCNV rates by gender, age and level of obesity in
children and adolescents
For the purpose of this study, 208 obese children and
adolescents with a BMI ≥95th percentile were consid-
ered based on a percentage above the 95th BMI percent-
ile as moderately (< 120% of the 95th percentile) and
severely (≥120% of the 95th percentile) obese (Fig. 7a).
This sample consisted predominantly of males (n = 123
or 59%) and children aged 2–9 years (n = 125 or 60%).
The majority of patients were classified as severely obese
(n = 160 or 77%). The prevalence of severe obesity was
higher than moderate obesity for both gender and age
groups (Fig. 7b) but there were statistically significantly
more males than females with severe obesity (105 males,
55 females; Fisher’s Exact test, p < 0.01); this sex-related
difference in obesity was observed in children but not in
adolescents aged 10–19 years (Additional file 4: Table S4).
Although a higher frequency of PCNVs was observed in
females (n = 23 or 27%) compared with males (n = 24 or
20%), no statistically significantly differences were ob-
served in the frequencies when compared by gender, age
at the time of testing, and obesity severity (Fig. 7c and d;
Additional file 5: Table S5). In boys, the prevalence of
PCNVs was greater in the severe obesity group (20% vs.
17%), particularly among children aged 2–9 years (18% vs.
11%), but was similar at adolescence (22%). In girls, the
prevalence of PCNVs was greater among the moderate
obesity group (35% vs. 30%), particularly among children
aged 2–9 years (35% vs. 25%), and correlated inversely in
adolescents (26% severe vs. 20% moderate obesity).
Discussion
This is the second study describing the use of CMA in
patients ascertained for syndromic obesity, the largest pub-
lished to date and also the first in a Brazilian cohort. We
identified PCNVs in 22% of patients (68 pathogenic events
in 61/279 subjects; Table 3), which is similar to the yield
reported by Vuillaume et al. in microarray studies with 100
patients with syndromic obesity [22]. The prevalence of
Table 2 Overall findings of microarray testing
Number %
Total number of cases 279 –
With imbalances 112 40
With pathogenic CNVs 61 22
With Known syndromes 47 17
Pathogenic imbalances a 68 –
Del 49 72
Dup 19 28
> 5 Mb 21 31
De novo 30 49
Inherited 6 10
Unknown 19 31
Not maternal 6 10
With likely pathogenic CNVs 6 2
With CNVs of uncertain significance 15 5
With likely benign CNVs 30 11
aPathogenic imbalances included 45 simple deletions or duplications, 4
unbalanced translocations, an insertional translocation, and 6 other complex
rearrangements believed to have been formed from the same rearrangement.
In the remaining 5 patients, the rearrangements were associated with a second-site
CNV arisen apparently independent which were classified as benign or of
uncertain significance
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1236270 Unk 1p36 terminal
deletion
KLHL17, AGRN, TAS1R3,* DVL1, VWA1,
MMP23B, GABRD
P2 34y F BMI 59.1 Del 1p36.33 734595-
2223317
1488722 Unk 1p36 terminal
deletion,
complex
KLHL17, AGRN, TAS1R3,* DVL1, VWA1,
















KLHL17, AGRN, TAS1R3,* DVL1, VWA1,
MMP23B, GABRD, PRKCZ, SKI*






2796445 Unk 1p36 terminal
deletion
KLHL17, AGRN, TAS1R3,* DVL1, VWA1,
MMP23B, GABRD, PRKCZ, SKI,*
TNFRSF14, PRDM16*






3228149 Unk 1p36 interstitial
deletion
CAMTA1, PER3, UTS2, RERE, H6PD*








1p21.3 deletion F3, PTBP2,* DPYD, MIR137






12059435 Unk 1p21.3 deletion PTBP2,* DPYD, MIR137, VCAM1,*
COL11A1, AMY2B, AMY2A, AMY1A*




1753945 Unk 1q21.1 distal
duplication
PRKAB2, CHD1L, GJA5, GJA8








ACP1,* TMEM18,* SNTG2, TPO,* MYT1L










PRLH, LRRFIP1, PER2, HDAC4, GPC1,*
CAPN10,* GPR35,* KIF1A, PASK, STK25*






6141675 Unk 2q37 terminal
deletion
AGAP1, PRLH, LRRFIP1, PER2, HDAC4,
GPC1,* CAPN10,* GPR35,* KIF1A, PASK,
STK25*











AGAP1, PRLH, LRRFIP1, PER2, HDAC4,













8178059 Unk 2q37 terminal
deletion,
complex
TRPM8, AGAP1, PRLH, LRRFIP1, PER2,















2327011 RPTOR, ACTG1, GCGR,* PCYT2, FASN,*
CSNK1D, UTS2R








6q16 deletion KLHL32, POU3F2, MCHR2,* SIM1,* GRIK2,
LIN28B,* ATG5




2564862 Unk 7q11.23 deletion FKBP6, FZD9, BCL7B, TBL2, MLXIPL,
STX1A,* CLDN3, ELN, LIMK1, RFC2,*
CLIP2, GTF2IRD1, GTF2I, NCF1




2616181 Unk 7q11.23 deletion FKBP6, FZD9, BCL7B, TBL2, MLXIPL,
STX1A,* CLDN3, ELN, LIMK1, RFC2,*
CLIP2, GTF2IRD1, GTF2I, NCF1










CLN8, CSMD1, DEFA1,* DEFB103A,
DEFB103B, DEFB104A, DEFB106A,
DEFB105A, DEFB107A, DEFB4A
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8104855 SLC6A13, WNT5B,* ADIPOR2,*
CACNA2D4, CACNA1C, FOXM1, TEAD4,
PARP11, KCNA1, NTF3, VWF, TNFRSF1A,*
SCNN1A, GAPDH, CD4, GNB3,* CD163,
APOBEC1, GDF3, SLC2A14, C3AR1








CLDN23, MFHAS1, PPP1R3B, LOC157273,
TNKS,* MSRA,* SOX7, MTMR9,* BLK,





Uncertain SGCG,¶ SACS, MIPEP










KANK1, DMRT1, SMARCA2, VLDLR,*
GLIS3, JAK2, RLN1, IL33,* KDM4C,
PTPRD*










KANK1, DMRT1, SMARCA2, VLDLR,*
GLIS3, JAK2, RLN1, IL33,* KDM4C,
PTPRD,* TTC39B






8606444 Unk 9p terminal
deletion
KANK1, DMRT1, SMARCA2, VLDLR,*
GLIS3, JAK2, RLN1, IL33,* KDM4C,
PTPRD*






9q34.3 deletion EHMT1,* CACNA1B








13q12.3 deletion POMP, SLC46A3, MTUS2, SLC7A1, UBL3,
KATNAL1, LINC00426, HMGB1,
ALOX5AP,* RXFP2, BRCA2*













1620472 Pat 16p13.1 deletion NDE1, MYH11,* ABCC1, ABCC6






NDE1, MYH11,* ABCC1, ABCC6








ATXN2L,* TUFM,* MIR4721, SH2B1,*
ATP2A1,* SPNS1








QPRT, PRRT2, SEZ6L2, DOC2A, ALDOA,
TBX6, MAPK3




604715 Pat 16p11.2 (BP 4-5)
duplication
QPRT, PRRT2, SEZ6L2, DOC2A, ALDOA,
TBX6, MAPK3






17p11.2 deletion COPS3, NT5M, MED9, PEMT,* RAI1,
SREBF1,* ATPAF2, DRG2, SMCR8,
MFAP4, SLC47A1, ALDH3A2, SPECC1






17p11.2 deletion TNFRSF13B, COPS3, NT5M, MED9,
PEMT,* RAI1, SREBF1,* ATPAF2,, DRG2,
SMCR8, MFAP4, SLC47A1, ALDH3A2,
SPECC1






17p11.2 deletion TNFRSF13B, COPS3, NT5M, MED9,
PEMT,* RAI1, SREBF1,* ATPAF2, DRG2,
SMCR8, MFAP4, SLC47A1, ALDH3A2,
SPECC1




3792390 Unk 17p11.2 deletion TNFRSF13B, COPS3, NT5M, MED9,
PEMT,* RAI1, SREBF1,* ATPAF2, DRG2,
SMCR8, MFAP4, SLC47A1, ALDH3A2,
SPECC1






17p11.2 deletion TNFRSF13B, COPS3, NT5M, MED9,
PEMT,* RAI1, SREBF1,* ATPAF2, DRG2,
SMCR8, MFAP4, SLC47A1, ALDH3A2,
SPECC1










AOC3, G6PC,* BRCA1,* SOST,* PPY,*
PYY,* TMEM101, HDAC5, ITGA2B,
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EFTUD2, PLCD3, CRHR1,* MAPT,
KANSL1









431211 Unk Uncertain PLIN2*








CD97, DDX39A, PKN1, PTGER1, GIPC1,
CASP14, NOTCH3, CYP4F11






22q11.2 deletion PRODH, DGCR2, DGCR14, CDC45,
TBX1,* GNB1L, TXNRD2, COMT,* DGCR8,
ZDHHC8






22q11.2 deletion PRODH, DGCR2, DGCR14, CDC45,
TBX1,* GNB1L, TXNRD2, COMT,* DGCR8,
ZDHHC8, PI4KA, SLC74A






22q11.2 deletion PRODH, DGCR2, DGCR14, CDC45,
TBX1,* GNB1L, TXNRD2, COMT,* DGCR8,
ZDHHC8, PI4KA, SLC74A




2843007 Pat 22q11.2 deletion PRODH, DGCR2, DGCR14, CDC45,
TBX1,* GNB1L, TXNRD2, COMT,* DGCR8,
ZDHHC8, PI4KA, SLC74A






PRODH, DGCR2, DGCR14, CDC45,
TBX1,* GNB1L, TXNRD2, COMT,* DGCR8,
ZDHHC8, PI4KA, SLC74A








HIC2, MAPK1,* GNAZ, BCR
















































28417187 ACAT1, ATM, POU2AF1, IL18,* ANKK1,
DRD2,* HTR3B, HTR3A, NNMT, BUD13,
APOA5,* APOA4,* APOC3,* APOA1,*
BACE1, IL10RA, CD3E, HYOU1, H2AFX,
CBL,* USP2, THY1, ARHGEF12, BSX,*
HSPA8, CLMP, NRGN, SLC37A2, TIRAP,
KCNJ1, KCNJ5,* OPCML












22331879 EPHA6, ARL6,* STG3GAL6, COL8A1,
CCDC80, BOC, ZDHHC23, ZBTB20, GAP43,
LSAMP, DRD3
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PCNVs in children and adolescents did not differ signifi-
cantly between gender and age groups, and obesity severity
(Fig. 7). Nevertheless, females had a higher detection rate of
PCNVs in comparison to males (27% females and 20%
males; overall), with the highest differences (35% females
and 11% males) found in the younger age group (2–9 years)
with less severe grades of obesity (BMI < 1.2 x 95th percent-
ile). Whilst no single phenotypic feature could be investi-
gated for association with PCNV risk, due to the absence of
comprehensively phenotyping of patients, phenotype-
phenotype correlation analysis between cases with and
without PCNVs identified 12 pairs of phenotypes that were
significantly associated with the presence of PCNVs and
combining hypotonia, language impairments, abnormalities
of the external genitalia, and eye/vision problems at its core.
Of note, patients in our cohort were almost 10 times more
likely to manifest macrocephaly as compared to microceph-
aly. Even though 33% of macrocephalic patients displayed
PCNVs, macrocephaly did not associate with the presence
of PCNVs.
In the current study, we have identified known gen-
omic imbalance disorders in 47 patients, and, of them,
35 patients (13%) carry overlapping and recurrent CNVs
(Table 3; Fig. 3). In our cohort, imbalances that are
known to be causal for syndromic obesity were observed
in 23 patients (8.2%). The most commonly identified






















ZMYND11, DIP2C,* IDI1, ADRAB2, PFKP,*
KLF6, ARK1C1, AKR1C2, ARK1C3, AKR1C4,















ZMYND11, DIP2C,* IDI1, ADRAB2, PFKP,*
KLF6, ARK1C1, AKR1C2, ARK1C3, AKR1C4,
UCN3, IL15RA, IL2RA,* PFKFB3, PRKCQ,
GATA3, CDC123, CAMK1D, CCDC3,







TUBA3C, GJB2, CRYL1, SGCG, SACS,
MIPEP, GPR12, GTF3A, MTIF3,* POLR1D,
PDX1,* CDX2, POMP, SLC46A3, MTUS2,
SLC7A1, UBL3, KATNAL1, LINC00426










PRLHR,* PRDX3, BAG3, WDR11, FGFR2,*
ACADSB, BUB3, OAT, TCERG1L, PRAP1,
CYP2E1*





















KITLG, ATP2B1, SOCS2, LTA4H, RMST,
NR1H4*








13qter deletion EFNB2, MYO16, IRS2,* COL4A1,
ARHGEF7, F7, GAS6, CHAMP1




















460959 Mat Likely benign WDR1






1619614 Unk Rett syndrome-
like
CDKL5, RS1, PHKA2, PDHA1,* SH3KBP1













3867831 TGIF2 LX, PABPC5-AS1, PABPC5, PCDH11X
Abbreviations: M male, F female, Del deletion, Dup duplication, y years, m months, BMI body mass index, SD standard deviation, unk unknown, mat maternally
inherited, pat paternally inherited, not mat not maternally inherited; Genes in bold were listed in the CNV morbidity map of IDDs [34]. Underlined genes were
retrieved from the Text-mined Hypertension, Obesity and Diabetes candidate gene database (T-HOD), the Human Genome Epidemiology (HUGE) Phenopedia, and
from a list of obesity candidate genes curated from the literature [33]. Genes found at the intersection of at least two gene sets are highlighted (asterisks).
Patients 6-12, 14, 15, 18, 23, 28, 30-33, 35, 40-43, 46-48, 51, 52, 55, 56, 58-60) have been published previously as separate studies [36-38]
D’Angelo et al. Molecular Cytogenetics  (2018) 11:14 Page 10 of 18
syndromic forms of obesity were deletions of the
chromosomal regions 1p36, 2q37 and 17p11.2, which
collectively represented 5.4% of all cases, followed by
microdeletions of the 1p21.3 region (2 cases). In 6 other
syndromic obesity loci (2p25.3, 6q16, 9q34, 16p11.2
proximal and distal, 12p13.31), CNVs were found only
in one unrelated individual. The identification of CNVs
overlapping loci previously shown to be involved in syn-
dromic obesity further implicates them as risk factors
for obesity. As previously mentioned, SH2B1, SIM1,
PTBP2, PRLH, CAPN10, ACP1, TMEM18, EHMT1, and
GNB3 are relevant candidate and known genes for obes-
ity within these regions (Fig. 6), and POU3F2 [20],
HDAC4 [50], MYT1L [52], and RAI1 [53] were also can-
didate genes identified in these loci. Moreover, our gene
prioritization analysis identified 20 new genes of interest
to obesity overlapping these CNVs, among which we
highlight the potential importance of TAS1R3, encoding
a taste receptor differentially expressed in obese mice
[54]. This gene maps within the common deleted region
of patients with distal 1p36 deletion.
In addition to the above, we identified 4 patients with
recurrent deletions at the 22q11.2 DiGeorge syndrome
(DS) region (we also found a patient with duplication of
the same region), 4 patients with distal 22q11.2 recurrent
deletions, and 3 patients with overlapping deletions at 9p
terminal. As these CNVs arise in more than 2 unrelated
individuals, we implicate them as novel loci with a poten-
tial role in obesity susceptibility. A link between the
22q11.2 region with obesity is also supported by previous
works showing that 22q11.2DS deletion carriers have
increased rates of obesity [55–57], as well as reports of
patients presenting childhood obesity with hyperphagia
[58, 59]. Overweight and obesity (with or without hyper-
phagia) have also been described in a number of patients
with distal 22q11.2 deletions [60–63]. We identified 3
genes at 22q11.2 (TBX1, COMT and MAPK1) that could
confer susceptibility to obesity (Fig. 6). Although obesity is
not a reported feature of deletion 9p syndrome, weight ≥
90th percentile at birth or in childhood was documented
in 4 of a series of 10 patients with distal deletions of 9p
[64], further emphasizing the potential importance of this
region. Additionally, we recently detected a deletion at
9p24.3p24.2 in one further patient with syndromic
obesity using multiplex ligation-probe amplification
(unpublished data from our laboratory). The VLDLR,
IL33 and PTPRD genes were identified as the most
interesting genes for obesity-susceptibility within 9p24
(Fig. 6). Furthermore, we detected 2 patients with
Williams-Beuren syndrome (WBS) 7q11.23 deletions.
This region was already shown to be associated with
several endocrine and metabolic problems including
hypothyroidism, hypercalcemia, obesity and diabetes
[65, 66]. Two genes related to obesity, STX1A and
RFC2, map to this CNV interval (Fig. 6).
In this study we discovered recurrent CNVs at 1q21.1
and 16p13.1, which are known predisposing factors to IDDs
reported sometimes in patients exhibiting obesity [67, 68].
Moreover, CNVs at these loci were also documented in a
cohort study of syndromic obesity [22]. We also discovered
other CNVs overlapping loci involved in syndromic obesity
cases from the literature and DECIPHER. For instance,
patient 24 carry a deletion overlapping the critical region of
the 13q12.3 microdeletion syndrome described by Bartholdi
et al. in 3 unrelated patients, two of whom with obesity
[69]. This deletion was further associated with obesity in a
patient from DECHIPER (case 282,282). Five genes map to
the common CNV interval (Fig. 4a), among them
ALOX5AP whose expression was linked to obesity and
insulin resistance [70]. Likewise, patient 38 carry a deletion
at 19p13.12 partially overlapping with those reported in 3
patients from literature, one of them with obesity [71]. We
found 2 other patients in DECIPHER with deletions at this
Fig. 3 Known genomic imbalance disorders detected in patients.
Imbalances that are known to be causal for syndromic obesity are
indicated (stars). The genes in parentheses are identifiers of genomic
locations. WBS: William-Beuren syndrome; SMS: Smith-Magenis
syndrome; DG: DiGeorge syndrome; KS: Kleefstra syndrome
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locus in addition to obesity (cases 255,743 and 265,764).
These cases share a 440-kb SRO encompassing 9 genes,
including NOTCH3 (Fig. 4b). The Notch signaling has
recently emerged as a key player in regulating metabolism
[72]. We also identified a case of 19p13.2 duplication in-
volving the NFIX gene associated with a Sotos syndrome-
like phenotype [73]. This CNV was associated with a 430-
kb 9p22.1 duplication that encompassed the entire PLIN2
gene, which is involved in the control of energy balance
[74]. Notably, CNV in this gene has previously been identi-
fied in a patient with syndromic obesity [22].
Other than CNVs overlapping known genomic disorders
loci, 14 patients had other chromosomal defects that are
known to be clinically relevant, among which 4 over-
lapped with loci previously implicated in obesity. The
distal portion of the 3q11.2q13.31 duplication in patient
49 (Fig. 5a) partially overlaps with a 2.76-Mb 3q13.31
duplication found in 2 brothers with syndromic obesity
[22], and with a 9.8-Mb 3q13.13q13.32 duplication
reported in association with obesity from DECIPHER
(case 314,391). The common region of overlap involves 5
genes and among them ZBTB20 is implicated in Primrose
syndrome associated with several endocrine features and
obesity (OMIM #259050). The large 13q11q12.3 duplica-
tion in our patient 53 (Fig. 5b) overlaps with a 1.2-Mb
13q12.12 duplication also found in our patient 19 and
with another 2-Mb 13q12.11q12.12 duplication detected
among cases with moderate and extreme obesity [75].
This region involves the gene SGCG with expression in
adipose tissues and associated with type 2 diabetes [76].
Patient 57 carry an 8.5-Mb 13q33.2q34 deletion encom-
passing the ID gene CHAMP1 (Fig. 5c), which partially
overlaps with deletions at 13q34 found in 6 other patients
with syndromic obesity reported by Vuillaume et al. [22]
and Reinstein et al. [21]. Of interest, the deleted region in
each of the 7 cases overlaps the obesity-associated gene
GAS6 [77]. The 14q11.2 microduplication found in our
patient 58 (Fig. 5d), including the SUPT16H and CHD8
genes, was also identified in one patient with syndromic
obesity reported by Vuillaume et al. [16]. No candidate
genes for obesity were associated with this locus. Although
there is one case of 14q11.2 deletion that was reported
with severe obesity, it included a large more proximal
segment of 14q11.2, which contains a strong obesity
candidate gene [14].
Finally, in a total of 51 patients the CNVs were classified
as potentially pathogenic (2.1%), VUS (4.7%) or likely
benign variants (11.5%). Overall, a number of interesting
genes that could play a role in obesity susceptibility have
been identified within these CNVs (e.g. ASTN2, APOA2,
PARK2, LINGO2, PLCB1, PTEN, and CIDEA). More
importantly, we identified a new and de novo 340-kb
16p13.2 duplication that encompasses the entire USP7
gene. Although its pathogenicity is not certain, since
Fig. 4 Schematic alignment using the UCSC Genome Browser custom track tools (hg19) showing the regions of overlap between the deleted
segments detected in (A) patient 24 (this study), DECIPHER case 282,282, and patients 1 and 2 of Bartholdi’s study [69]; (B) patient 38 (this study),
DECIPHER case 255,743 and 265,764, and patient 1 of Bonaglia’s study [71]. The inheritance of the CNVs and the protein-coding genes located
within them are shown. The inner light gray boxes show the smallest regions of overlapping deletions
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similar duplications have not been reported in the litera-
ture, there is one reported patient with larger duplication
at the USP7 locus presenting with severe early-onset obes-
ity and hyperphagia [78]. Of note, USP7 has been identi-
fied as an integral component of MAGEL2 and TRIM27
ubiquitin ligase complex, which plays an important role in
hypothalamic function [79]. Moreover, deletion or muta-
tion of USP7 has been shown to result in a neurodeve-
lopmental disorder with overlapping symptoms to
Schaaf-Yang syndrome (OMIM #615547), caused by
mutations of MAGEL2 [78]. There are 5 de novo dupli-
cation events overlapping USP7 (400-kb to 1.2-Mb)
reported in DECIPHER with no additional changes de-
tected. These included 3 patients (cases 269,501,
281,449 and 258,037) with delayed speech and language
development as common features and 2 patients (cases
254,000 and 267,094) with no phenotypic description.
One of the limitations of our study is that additional in-
dependent risk factors were not considered, including
unidentified genetic factors and those being epigenetic,
environmental, or stochastic in origin. Future investiga-
tions of genes within disease-specific CNVs detected in
the present cohort are also needed. Future directions
will involve whole exome sequencing (WES) in patients
Fig. 5 Schematic alignment using the UCSC Genome Browser custom track tools (hg19) showing the regions of overlap between deleted (black) and
duplicated (grey) segments detected in (a) patient 19 (this study), DECIPHER case 314,391 and brothers P1010 and P1011 of Vuillaume’s study [22]; (b)
patients 19 and 53 (this study) and one individual described by Wang et al. [75]; (c) patient 57 (this study), case P2007 of Vuillaume’s study [22] and
families 1 and 2 of Reinstein’s study [21]; (d) patient 58 (this study), case P2023 of Vuillaume’s study [22], and one patient described by Terrone et al.
[14]. Vertical lines depict breakpoints that extended beyond the regions indicated here. The inheritance of the CNVs and the protein-coding genes
located within them are shown. The inner light gray boxes show the smallest regions of overlap
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that did not reach a diagnosis to estimate the contribu-
tion of single gene mutations in the genetic causation
of syndromic obesity. This will allow isolate genes that
cause or may affect susceptibility to obesity in humans,
advancing our understanding of the molecular mecha-
nisms involved in body weight regulation and provide
clues for therapeutic intervention in obesity.
Conclusion
Understanding the genetics of obesity has proven diffi-
cult. Although it is likely that not all of the PCNVs
detected in the current study are directly causative of
obesity, we found that 23/279 (8.2%) of our patients
carried rare CNVs at 10 loci already known to increase
the risk of obesity. We identified 3 patients with over-
lapping deletions at 9p terminal, 4 patients with dele-
tions of 22q11.2DS and 4 patients with deletions at
distal 22q11.2, which thus emerge as new putative
obesity-susceptibility loci. In addition, we found that
CNVs in at least 6 other cases overlapped with loci pre-
viously implicated in syndromic obesity, including a
new patient with deletion at chromosome 13q34. This
Fig. 6 shows 87 prioritized genes and their positions within PCNVs, but also likely PCNVs, VUS and benign CNVs (asterisk). Prioritized genes were retrieved
by at least 2 independent gene sets, including obesity candidate genes collected from the T-HOD (Text-mined Hypertension, Obesity and Diabetes) and
HUGE (Human Genome Epidemiology) database, a list of genes with evidence for playing a role in obesity curated from literature [33], and genes in the
CNV morbidity map for IDDs [34]
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locus is particularly interesting because our new case
brings to 7 the number of patients in whom such
defects have been described in association with obesity.
Overall, we found CNVs that further implicate genes
previously associated with obesity such as PTBP2,
TMEM18, MYT1L, POU3F2, SIM1, SH2B1 and GNB3,
and also identified other potentially relevant candidate
genes including TAS1R3, ALOX5AP, and GAS6. Our
study highlights the significant value of chromosomal
microarrays in providing not only a genetic diagnosis
for syndromic causes of obesity but in uncovering genes
relevant to human obesity.
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